Polypeptide combination dosage regimens
OwnerLars HANSENinventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method of treating and/or preventing a disease or disorder in a subject, the method comprising administering to the subject about 1 mg to about 15 mg of an amylin receptor (AMYR) agonist and about 0.1 mg to about 10 mg of a GLP-1 receptor (GLP-1R) agonist (e.g. a GLP-1R/glucagon receptor dual agonist). Also provided are corresponding compositions and kits.
Claims91
A method for treating and/or preventing a disease or disorder in a subject, the method comprising administering to the subject
- (a) about 1 mg to about 15 mg of an amylin receptor (AMYR) agonist;
- and
- (b) about 0.1 mg to about 10 mg of a GLP-1 receptor (GLP-1R) agonist.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-115. (canceled)
Dependencies are inferred from the claim text.